Trust Signals
Key Takeaways
- EDTA plasma (lavender-top tube) is the validated matrix for all major BNP immunoassays; serum is not appropriate.
- BNP measured in serum runs roughly 10 to 25 percent lower than in paired EDTA plasma due to protease activity released during clot formation.
- The landmark 100 pg/mL rule-out cutoff (Maisel et al., NEJM 2002, n = 1,586) was derived exclusively from EDTA plasma and cannot be applied to serum results.
- NT-proBNP, by contrast, is stable in both serum and EDTA plasma because it lacks the neutral-endopeptidase cleavage site found on BNP.
- At room temperature, BNP in EDTA plasma is stable for roughly 4 hours; beyond that, refrigeration or freezing at minus 20 Celsius is required to prevent clinically significant degradation.
Direct Answer: Should BNP Be Measured in Serum or Plasma?
Plasma, specifically EDTA-anticoagulated plasma collected in a lavender-top tube, is the correct matrix for BNP measurement. Serum produces systematically lower and variable BNP concentrations because clot-formation proteases degrade this 32-amino-acid peptide before analysis. Every major assay manufacturer validates BNP immunoassays in EDTA plasma, not serum.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Why does sample type matter for BNP?
- What is the biochemical mechanism behind BNP degradation in serum?
- Evidence ledger: how confident should you be in these claims?
- How stable is BNP in plasma after collection?
- BNP versus NT-proBNP: which wins on sample flexibility?
- What most lab guides get wrong about BNP sample handling
- How to read a BNP assay package insert yourself
- How do clinical cutoffs depend on sample matrix?
- What else shifts BNP values independent of heart disease?
- Frequently asked questions
- Sources
Why Does Sample Type Matter for BNP?
BNP (brain natriuretic peptide, now correctly called B-type natriuretic peptide) is a 32-amino-acid polypeptide secreted by ventricular cardiomyocytes in response to wall stress. It is released as a 108-amino-acid prohormone (proBNP-108) that is cleaved into the active BNP-32 fragment and the inactive N-terminal fragment NT-proBNP-76. It is BNP-32 that most "BNP" assays measure.
BNP-32 is inherently labile. Its ring structure, formed by a disulfide bond between cysteines at positions 10 and 26, is a cleavage target for neutral endopeptidase 24.11 (neprilysin). Platelets and leukocytes liberate additional proteases during the coagulation cascade. When blood is collected into a serum tube and allowed to clot, BNP-32 is exposed to this protease environment for the full clotting time plus any pre-centrifugation wait, typically 30 minutes or more. The result is partial to substantial degradation before the sample ever reaches the analyzer.
What Is the Biochemical Mechanism Behind BNP Degradation in Serum?
Three distinct pathways reduce BNP concentration in serum compared to plasma:
- Neprilysin (NEP, CD10) cleavage. Neprilysin is present on vascular endothelium, renal tubules, and circulates in a soluble form. It cleaves BNP-32 at multiple sites within the ring region. EDTA does not inhibit neprilysin directly, but it does block platelet activation, which reduces the overall protease burden.
- Platelet-released proteases. During clot formation, activated platelets release cathepsin D, plasminogen activators, and other serine proteases. These contribute to peptide fragmentation in the serum matrix. EDTA chelates calcium ions (Ca2+), which are obligate cofactors for the coagulation cascade and platelet activation. Without calcium, platelets cannot undergo the conformational changes that release granular contents.
- Adsorption to fibrin clot. Some fraction of BNP physically adsorbs to the fibrin meshwork during clot retraction. This fraction is excluded from the serum supernatant regardless of enzymatic activity.
The net consequence: studies comparing paired serum and EDTA plasma samples drawn simultaneously show serum BNP running 10 to 25 percent below plasma, with the gap widening when clotting time or pre-centrifugation delay increases. Because the magnitude of this reduction is unpredictable for any individual sample, serum results cannot be corrected with a simple multiplication factor.
Evidence Ledger: How Confident Should You Be in These Claims?
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| EDTA plasma is the validated matrix for BNP immunoassays | Manufacturer package inserts (regulatory-grade analytical validation) | Definitive: EDTA plasma required | High |
| Serum BNP is 10 to 25% lower than paired EDTA plasma | Multiple analytical comparison studies (e.g., Clerico et al., Clin Chem Lab Med; Wu et al., Clin Chem) | Serum consistently lower | High |
| Platelet protease release explains serum degradation | Mechanistic/laboratory studies; in vitro platelet inhibition experiments | Directionally confirmed | Moderate |
| BNP stable in EDTA plasma for ~4 hours at room temperature | Analytical stability studies (multiple authors, various platforms) | Clinically meaningful degradation beyond 4 hours | Moderate |
| 100 pg/mL cutoff derived from EDTA plasma cohort | Prospective human RCT-equivalent diagnostic study (Maisel et al., NEJM 2002, n=1,586) | Cutoff validated in plasma only | High |
| NT-proBNP stable in serum and EDTA plasma equally | Analytical comparison studies; manufacturer data | No clinically significant matrix effect | High |
| Obesity lowers BNP relative to filling pressures | Multiple cross-sectional and cohort studies | Lower BNP in obese patients at equivalent cardiac stress | High |
| Hemolysis degrades BNP results | Interference studies (manufacturer and independent) | Significant hemolysis causes degradation and matrix interference | Moderate |
How Stable Is BNP in Plasma After Collection?
Stability is a practical concern in every lab and point-of-care setting. The following represents the consensus from published stability studies across multiple immunoassay platforms. Exact figures vary by platform; always check your specific assay insert.
| Condition | Approximate Stability Window | Clinical Risk if Exceeded |
|---|---|---|
| EDTA plasma, room temperature (15 to 25 C) | Up to approximately 4 hours | Measurable BNP decrease; may affect decisions near thresholds |
| EDTA plasma, refrigerated (2 to 8 C) | Up to approximately 24 hours in most studies | Low risk within this window |
| EDTA plasma, frozen at minus 20 C | Weeks to months; single freeze-thaw preferred | Each freeze-thaw cycle causes some loss; limit cycles |
| Serum, room temperature | Not validated; ongoing degradation from clot formation onward | High: results systematically low and unpredictable |
| Whole blood in EDTA tube, not centrifuged, room temperature | Approximately 4 hours before significant decline in most studies | Centrifuge promptly; do not leave whole blood sitting |
The underlying chemistry: BNP in EDTA plasma still faces soluble neprilysin circulating in the plasma compartment. EDTA removes the platelet and coagulation contribution but does not fully suppress soluble NEP. This is why even plasma stability is time-limited at room temperature.
BNP vs. NT-proBNP: Which Wins on Sample Flexibility?
| Feature | BNP-32 | NT-proBNP-76 | Winner |
|---|---|---|---|
| Validated sample matrix | EDTA plasma only (primarily) | Serum or EDTA plasma (either acceptable) | NT-proBNP |
| Stability at room temperature | Approximately 4 hours in EDTA plasma | Up to 72 hours in most studies | NT-proBNP |
| Neprilysin inhibitor (sacubitril) interference | BNP rises artifactually on sacubitril because BNP is a neprilysin substrate; plasma BNP increases but is not biologically active | NT-proBNP not cleaved by neprilysin; reflects true cardiac stress on sacubitril therapy | NT-proBNP for patients on sacubitril/valsartan |
| Renal clearance sensitivity | Cleared by neprilysin and natriuretic peptide receptor-C; less renal-dependent | Primarily renally cleared; rises steeply with GFR reduction | BNP in severe CKD (lower false elevation) |
| Point-of-care availability | Multiple validated POC platforms exist | Fewer POC options historically | BNP |
| Assay cross-platform comparability | Poor: values differ substantially between Beckman, Abbott, Siemens | Also poor between platforms but slightly better standardized | Neither: always use same platform longitudinally |
| Half-life in circulation | Approximately 20 minutes | Approximately 60 to 120 minutes | NT-proBNP for detecting chronic elevation |
Honest concession: For routine heart failure screening and follow-up in patients not on sacubitril, NT-proBNP wins on nearly every pre-analytical dimension. The case for BNP is strongest in point-of-care settings and in patients with advanced renal failure where NT-proBNP's renal dependence inflates values.
What Most Lab Guides Get Wrong About BNP Sample Handling
Most published "specimen collection" guides state the tube type correctly (lavender top, EDTA) but omit four critical operational realities:
- Order of draw matters. If EDTA tubes are drawn after a coagulation tube that was difficult to fill, platelet activation and tissue thromboplastin contamination from needle entry can carry over. Draw order should follow CLSI H3-A6 guidelines; EDTA tubes should be drawn before serum tubes when BNP is the priority.
- Inadequate mixing is functionally similar to serum. An EDTA tube that is not properly inverted 8 to 10 times immediately after collection will form microclots. These microclots generate local protease activity and adsorb BNP in the same way serum clot does. An unmixed lavender-top tube partially negates the EDTA advantage.
- The sacubitril/valsartan (Entresto) confound is massively underreported in collection guides. Sacubitril blocks neprilysin, so BNP accumulates in plasma, but this accumulated BNP does not reflect proportionally greater cardiac stress. A patient on sacubitril may have a BNP of 300 pg/mL with well-controlled heart failure. Virtually no tube-color guide mentions this drug interaction despite its clinical importance.
- Lipemia interferes with some BNP assay formats. Highly lipemic samples can cause optical interference in turbidimetric assays and matrix effects in some immunoassays. Labs rarely flag this. If a BNP result is implausibly low in a post-prandial lipemic sample, pre-analytical lipemia should be considered.
How to Read a BNP Assay Package Insert Yourself
If you receive a BNP result and want to verify the sample requirements, locate the assay's package insert (available on the manufacturer's website under IFU or Directions for Use). Look for these sections:
- "Specimen" or "Sample": Lists acceptable matrices (should say "EDTA plasma" as primary). Note whether lithium heparin or heparin plasma is also listed as acceptable, and whether serum is explicitly excluded.
- "Specimen Stability": Gives exact hours and temperatures. These are the legally validated figures; published literature figures may differ.
- "Interferences": Lists hemolysis index cutoffs (often expressed as H-index), lipemia index cutoffs (L-index), and drug interferences. Cross-check for sacubitril/LBQ657 if your patient takes Entresto.
- "Reference Range" or "Expected Values": Note the population demographics. Most manufacturers derived reference ranges in adults without heart failure, but ranges differ by age and sex subgroup. A BNP of 50 pg/mL in an 80-year-old woman may be in the upper quartile of the manufacturer's reference range for that group.
- "Calibration": Calibrator source (usually recombinant BNP-32) and traceability statement. Lack of standardization across manufacturers is why a value of 150 pg/mL on a Beckman analyzer is not equal to 150 pg/mL on a Siemens analyzer.
How Do Clinical Cutoffs Depend on Sample Matrix?
The foundational BNP diagnostic study (Maisel et al., NEJM 2002) enrolled 1,586 patients presenting with acute dyspnea across emergency departments in the Breathing Not Properly Multinational Study. All samples were EDTA plasma. The area under the ROC curve for BNP at 100 pg/mL was 0.91 for distinguishing heart failure from non-cardiac dyspnea. Sensitivity was approximately 90 percent and specificity approximately 76 percent at that cutoff.
If serum were used in that cohort, a 15 percent average reduction would shift many values below 100 pg/mL. At a true plasma BNP of 110 pg/mL, a 15 percent serum reduction yields 93.5 pg/mL. That patient would be misclassified as low probability for heart failure. This is not a theoretical concern; it is arithmetic that directly follows from the known matrix difference.
Age-stratified and sex-stratified cutoffs exist and are clinically relevant. BNP rises with age and is lower in men than women at equivalent filling pressures in some cohorts. No serum-based cutoffs have been prospectively validated in large diagnostic studies because no major investigator has pursued serum as the preferred matrix.
What Else Shifts BNP Values Independent of Heart Disease?
Clinicians and patients evaluating a BNP result should recognize that the following factors affect BNP concentration in blood regardless of ventricular function:
- Obesity: Multiple studies document lower BNP in obese patients relative to measured filling pressures, possibly due to greater BNP clearance via natriuretic peptide receptor-C (NPR-C), which is expressed on adipocytes. Obese patients with heart failure can have BNP below 100 pg/mL.
- Renal failure: BNP is less renally cleared than NT-proBNP, but moderate to severe CKD still elevates BNP independent of cardiac filling pressure.
- Atrial fibrillation: Atrial stretch in AF raises BNP even without ventricular dysfunction. Some guidelines suggest using higher cutoffs in AF.
- Acute coronary syndrome: BNP rises within hours of myocardial ischemia, even without pre-existing heart failure, due to acute wall-motion abnormalities.
- Sepsis and critical illness: Multiple cytokines upregulate BNP gene expression; elevated BNP in ICU patients may reflect sepsis physiology rather than primary cardiac dysfunction.
- Thyroid disease: Hyperthyroidism raises BNP; hypothyroidism lowers it. Thyroid status should be considered when BNP is unexpectedly discordant with clinical findings.
Frequently Asked Questions
Plasma, specifically EDTA-anticoagulated plasma collected in a lavender-top tube, is the correct and validated sample type. BNP degrades significantly in serum due to protease activity during the clotting process, producing systematically lower and less reproducible results. All major assay manufacturers validate their BNP immunoassays against EDTA plasma.
During clot formation in a serum tube, platelets activate and release proteases including neutral endopeptidase and cathepsins. These enzymes cleave BNP, a 32-amino-acid peptide that is already metabolically labile. EDTA chelates calcium, blocking the coagulation cascade and platelet activation, thereby preserving BNP concentration.
Published comparisons show BNP values in serum are roughly 10 to 25 percent lower than paired EDTA plasma samples. The degree of reduction varies with clot contact time and temperature, making serum results unpredictable and unsuitable for clinical thresholds validated in plasma.
Heparin plasma is generally acceptable for most BNP immunoassays and causes less protease activity than serum, but EDTA plasma remains the primary validated matrix. Some assay inserts specifically warn that heparin can interfere at high concentrations. Always check the specific assay package insert.
In EDTA plasma kept at room temperature, BNP is generally stable for roughly 4 hours. At 4 degrees Celsius it is stable for up to 24 hours in most studies. Freeze-thaw cycles cause measurable degradation; samples should be frozen at minus 20 Celsius or colder for longer storage.
The most widely cited cutoff for ruling out heart failure is 100 pg/mL (Maisel et al., NEJM 2002), derived entirely from EDTA plasma samples. Using serum would produce values below this threshold in some true-positive patients, risking false-negative results. The cutoff cannot be directly transposed to serum.
NT-proBNP is more stable than BNP because it lacks the ring structure targeted by neutral endopeptidase. It can be measured in serum or EDTA plasma with comparable results, making it less sample-sensitive. However, NT-proBNP uses different clinical cutoffs and is not interchangeable with BNP numerically.
Use a lavender-top (purple-top) tube containing EDTA. Mix gently by 8 to 10 inversions immediately after collection. Do not use red-top (serum), gold-top (SST), or green-top (heparin) tubes unless your specific assay has been validated in that matrix. Centrifuge promptly and process within 4 hours at room temperature.
Yes. Significant hemolysis releases intracellular contents including proteases and can cause both matrix interference and BNP degradation. Most assay manufacturers flag samples with a hemolysis index above a defined threshold as unacceptable. The degree of impact varies by assay platform.
BNP immunoassays use different antibody pairs that recognize different epitopes on the 32-amino-acid BNP molecule, and calibrators differ between manufacturers. Results from the Beckman Access, Abbott Architect, and Siemens platforms are not numerically equivalent. Clinical cutoffs are assay-specific and should never be swapped between platforms.
Yes. Obesity is consistently associated with lower BNP levels relative to cardiac filling pressures, a finding documented in multiple cohort studies. This means obese patients may have heart failure with BNP values below the standard 100 pg/mL threshold. Age, sex, and renal function also influence reference ranges.
Sources
- Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. New England Journal of Medicine. 2002;347(3):161-167.
- Clerico A, Prontera C, Emdin M, et al. Analytical and clinical evaluation of a fully automated electrochemiluminescence immunoassay for the determination of BNP. Clinical Chemistry and Laboratory Medicine. 2005;43(3):304-310.
- Wu AH, Packer M, Smith A, et al. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure. Clinical Chemistry. 2004;50(5):867-873.
- Apple FS, Panteghini M, Ravkilde J, et al. Quality specifications for B-type natriuretic peptide assays. Clinical Chemistry. 2005;51(3):486-493.
- McCullough PA, Sandberg KR. B-type natriuretic peptide and renal disease. Heart Failure Reviews. 2003;8(4):355-358.
- Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109(5):594-600.
- Januzzi JL, Camargo CA, Anwaruddin S, et al. The N-terminal pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. American Journal of Cardiology. 2005;95(8):948-954.
- Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology. 2017;70(6):776-803.
- Clinical and Laboratory Standards Institute. Collection of Diagnostic Venous Blood Specimens. CLSI H3-A6. Wayne, PA: CLSI; 2007.
- Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. European Journal of Heart Failure. 2004;6(3):261-268.